Screening for metabolic dysfunction-associated fatty liver disease: Time to discard the emperor's clothes of normal liver enzymes?
World J Gastroenterol
; 30(22): 2839-2842, 2024 Jun 14.
Article
in En
| MEDLINE
| ID: mdl-38947289
ABSTRACT
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most prevalent chronic liver condition worldwide. Current liver enzyme-based screening methods have limitations that may missed diagnoses and treatment delays. Regarding Chen et al, the risk of developing MAFLD remains elevated even when alanine aminotransferase levels fall within the normal range. Therefore, there is an urgent need for advanced diagnostic techniques and updated algorithms to enhance the accuracy of MAFLD diagnosis and enable early intervention. This paper proposes two potential screening methods for identifying individuals who may be at risk of developing MAFLD Lowering these thresholds and promoting the use of noninvasive liver fibrosis scores.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Mass Screening
/
Non-alcoholic Fatty Liver Disease
/
Liver
Limits:
Humans
Language:
En
Journal:
World J Gastroenterol
/
World j. gastroenterol
/
World journal of gastroenterology
Year:
2024
Document type:
Article